Filing Details

Accession Number:
0001567619-22-001197
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-01-14 16:32:12
Reporting Period:
2022-01-12
Accepted Time:
2022-01-14 16:32:12
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1770787 10X Genomics Inc. TXG () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1246406 Bradford Crutchfield C/O 10X Genomics, Inc.
6230 Stoneridge Mall Road
Pleasanton CA 94588
Chief Commercial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Class A Common Stock Acquisiton 2022-01-12 17,000 $1.16 114,653 No 4 M Direct
Class A Common Stock Disposition 2022-01-12 6,195 $117.53 108,458 No 4 S Direct
Class A Common Stock Disposition 2022-01-12 5,185 $118.32 103,273 No 4 S Direct
Class A Common Stock Disposition 2022-01-12 1,017 $119.28 102,256 No 4 S Direct
Class A Common Stock Disposition 2022-01-12 1,100 $120.93 101,156 No 4 S Direct
Class A Common Stock Disposition 2022-01-12 3,200 $121.77 97,956 No 4 S Direct
Class A Common Stock Disposition 2022-01-12 100 $122.94 97,856 No 4 S Direct
Class A Common Stock Disposition 2022-01-12 100 $123.53 97,756 No 4 S Direct
Class A Common Stock Disposition 2022-01-12 100 $124.44 97,656 No 4 S Direct
Class A Common Stock Disposition 2022-01-12 3 $125.00 97,653 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Class A Common Stock Stock Option (right to buy) Disposition 2022-01-12 17,000 $0.00 17,000 $1.16
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
409,000 2027-02-03 No 4 M Direct
Footnotes
  1. The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
  2. This transaction was executed in multiple trades at prices ranging from $116.89 to $117.87. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
  3. This transaction was executed in multiple trades at prices ranging from $117.90 to $118.84. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
  4. This transaction was executed in multiple trades at prices ranging from $118.985 to $119.83. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
  5. This transaction was executed in multiple trades at prices ranging from $120.31 to $121.29. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
  6. This transaction was executed in multiple trades at prices ranging from $121.47 to $122.35. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
  7. This option, originally for 800,000 shares, of which 391,000 shares have been exercised, vested as to one-fourth of the shares on February 2, 2018 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.